Assuming a preferential central action of GLP1/E, we conducted label-free, quantitative proteomic analyses in the hypothalamus of the two models of PCOS, after chronic treatment with the di-agonist, as a means to disclose putative pathways for the metabolic actions of the di-agonist, and the basis for the partially differential responses between the two models of PCOS, which diverge also in terms of phenotypic presentation
Initially, GLP-1 agonists were explored as a treatment for type 2 diabetes
Quitting provides benefits extending far beyond GERD while enhancing tissue healing capacity
This is where many people introduce errors
doi: 10.1172/jci.insight.164221 70 JiangS.XieS.LvD.ZhangY.DengJ.ZengL.et al
Official TSA policy on traveling with insulin syringes, vials, and medical supplies through airport security